Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer

NCT ID: NCT01978834

Last Updated: 2015-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

560 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed for clinical validation of the novel ultrasound device (Bindex®, Bone Index Finland Ltd.). In a preliminary study technique has been validated in Finnish elderly woman population with 285 healthy and 56 osteoporotic subjects (n = 341 in total). Significant and good correlation was observed between Density Index (DI) determined with Bindex and femoral bone mineral density determined with DXA (r = 0.65 - 0.70). In addition, with determination of 90% sensitivity and specificity thresholds, significant number (65-75%) of patients could be diagnosed without additional verification with DXA.

First, the thresholds for DI will be determined by measuring 70 osteoporotic and 70 healthy patients (n = 140) with Bindex and DXA within four decades of age; age 50 to 59 years, age 60 to 69 years, age 70 to 79 years, and age 80 to 89 years. The feasibility of DI for diagnostics of osteoporosis and evaluation of bone mineral density (BMD) will be assessed. The thresholds for the BMD estimate obtained with DI will be determined for osteoporotic and non-osteoporotic patients. For fracture risk assessment, DI measurements are used to predict the outcome of currently available fracture risk assessment tools.

1. To investigate optimal configuration of ultrasound parameters and patient characteristics for prediction of proximal femur and lumbar spine BMD for women in each four decades of age; 50 to 59 years, 60 to 69 years, 70 to 79 years, and 80-89 years.
2. To develop national diagnostic thresholds for DI in prediction of osteoporosis status with a reference female population (American-Caucasian) in each four decades of age; 50 to 59 years, 60 to 69 years, 70 to 79 years, and 80-89 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Data will be stored by Park Nicollet Institute. Only data listed below will be given to the research team at Bindex for analyses.

The data for determination of diagnostic threshold for DI in North American population will be analyzed by Bone Index Finland. The data will include following parameters:

* Age in years
* Weight
* Height
* Cortical thickness values at each location
* Density Index values
* Raw data on ultrasound signals.
* DXA measurement data
* Identification code (Uniquely created identification code given to a subject, does not carry any information on subject but enables tracing if needed.)
* Data from Appendix A, excluding patient name and medical record number

Risk factors will be collected in a separate questionnaire (Appendix A).

1. Name
2. Medical Record Number
3. Weight (kg)
4. Height (cm)
5. Chair Stand test Can do easily; can do only with difficulty; cannot do

Risk Factors:
6. Previous fracture (Skeletal site, age at which fracture occured)
7. Parent fractured hip (Yes, No)
8. Current smoking (Yes, No)
9. Glucocorticoid Use (Yes, No)
10. Rheumatoid arthritis (Yes, No)
11. Alcohol 3 or more units per day (Yes, No)
12. Osteoporosis medication, type (e.g. alendronate, bisphosphonates), start- and end-date (Within the past five years)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female sex
* Age 50 to 89 years

Exclusion Criteria

* Those who have opted out of being contacted for research on their general Park Nicollet clinic consent will not be recruited by mail
* Inability to sign consent form due to cognitive impairment. Those with dementia (ICD-9 diagnosis codes 331.0, 294.1, 294.10, 294.11, or 294.8) will excluded from mailed recruitment
* Measurement of hip BMD is not feasible (for example, those who have had bilateral hip replacement surgeries or who cannot have central DXA because of their body weight)
* Open leg or arm wounds at sites where ultrasound measurements are supposed to be taken, precluding such measurements
Minimum Eligible Age

50 Years

Maximum Eligible Age

89 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

HealthPartners Institute

OTHER

Sponsor Role collaborator

Bone Index Finland Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John T Schousboe, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

HealthPartners Institute

Janne P Karjalainen, PhD

Role: STUDY_DIRECTOR

Bone Index Finland Ltd

Ossi Riekkinen, PhD

Role: STUDY_DIRECTOR

Bone Index Finland Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Park Nicollet Institute

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BoneIndex02

Identifier Type: OTHER

Identifier Source: secondary_id

Bind02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.